Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 May;95(5):1974–1978. doi: 10.1172/JCI117881

High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.

C Ross 1, M Svenson 1, M B Hansen 1, G L Vejlsgaard 1, K Bendtzen 1
PMCID: PMC295769  PMID: 7738163

Abstract

This paper demonstrates and characterizes naturally occurring antibodies to interferon (IFN) in human IgG preparations. In vitro neutralization of the antiviral effect of IFN alpha and IFN beta, but not IFN gamma, was observed in 12 of 15 normal IgG preparations. The neutralizing capacity was higher against rIFN alpha 2A and rIFN alpha 2C than against lymphoblastoid IFN alpha and IFN beta. Frühsommer meningoencephalitis hyperimmune IgG and hepatitis-B hyperimmune IgG showed potent neutralization, whereas anti-rhesus D-, anti-rabies-, and anti-tetanus IgG showed weak neutralization. Saturable binding of 125I-rIFN alpha 2A was demonstrated only in those IgG preparations found to neutralize the antiviral effect of IFN. Significant correlation between IFN binding and neutralization capacity was observed. The antibodies bound with Fab to rIFN alpha 2A with an avidity of approximately 30 pM; the majority was of the IgG1 subclass. Maximum binding capacity was 490 pg rIFN alpha 2A/mg IgG. Cross-binding of rIFN alpha 2C, lyIFN alpha N1 and IFN beta occurred with 10 and 100-200 times lower activities than that of rIFN alpha 2A. There was no cross-binding with rIFN gamma or rIL-6. IgG preparations containing anti-IFN antibodies blocked the binding of 125I-rIFN alpha 2A to A549 cells. In conclusion, pharmaceutically prepared human IgG preparations contain variable but significant levels of high-avidity IFN alpha and IFN beta neutralizing antibodies.

Full text

PDF
1974

Images in this article

1976Image
on p.1976
1977Image
on p.1977

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonelli G., Currenti M., Turriziani O., Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis. 1991 Apr;163(4):882–885. doi: 10.1093/infdis/163.4.882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bendtzen K., Svenson M., Jønsson V., Hippe E. Autoantibodies to cytokines--friends or foes? Immunol Today. 1990 May;11(5):167–169. doi: 10.1016/0167-5699(90)90068-k. [DOI] [PubMed] [Google Scholar]
  3. Bocci V. What roles have anti-interferon antibodies in physiology and pathology? Ric Clin Lab. 1991 Jan-Mar;21(1):79–84. doi: 10.1007/BF02919115. [DOI] [PubMed] [Google Scholar]
  4. Caruso A., Bonfanti C., Colombrita D., De Francesco M., De Rango C., Foresti I., Gargiulo F., Gonzales R., Gribaudo G., Landolfo S. Natural antibodies to IFN-gamma in man and their increase during viral infection. J Immunol. 1990 Jan 15;144(2):685–690. [PubMed] [Google Scholar]
  5. De Maeyer-Guignard J., Cachard-Thomas A., De Maeyer E. Naturally occurring anti-interferon antibodies in Lou/c rats. J Immunol. 1984 Aug;133(2):775–778. [PubMed] [Google Scholar]
  6. De Maeyer-Guignard J., De Maeyer E. Natural antibodies to interferon-alpha and interferon-beta are a common feature of inbred mouse strains. J Immunol. 1986 Mar 1;136(5):1708–1711. [PubMed] [Google Scholar]
  7. Dwyer J. M. Manipulating the immune system with immune globulin. N Engl J Med. 1992 Jan 9;326(2):107–116. doi: 10.1056/NEJM199201093260206. [DOI] [PubMed] [Google Scholar]
  8. Hansen M. B., Ross C., Berg K. A sensitive antiviral neutralization bioassay for measuring antibodies to interferons. J Immunol Methods. 1990 Mar 9;127(2):241–248. doi: 10.1016/0022-1759(90)90074-6. [DOI] [PubMed] [Google Scholar]
  9. Hansen M. B., Svenson M., Abell K., Varming K., Nielsen H. P., Bertelsen A., Bendtzen K. Sex- and age-dependency of IgG auto-antibodies against IL-1 alpha in healthy humans. Eur J Clin Invest. 1994 Mar;24(3):212–218. doi: 10.1111/j.1365-2362.1994.tb00991.x. [DOI] [PubMed] [Google Scholar]
  10. Hansen M. B., Svenson M., Bendtzen K. Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera. Clin Exp Immunol. 1992 Jun;88(3):559–562. doi: 10.1111/j.1365-2249.1992.tb06487.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ikeda Y., Toda G., Hashimoto N., Umeda N., Miyake K., Yamanaka M., Kurokowa K. Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis. Clin Exp Immunol. 1991 Jul;85(1):80–84. doi: 10.1111/j.1365-2249.1991.tb05686.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mogensen K. E., Daubas P., Gresser I., Sereni D., Varet B. Patient with circulating antibodies to alpha-interferon. Lancet. 1981 Nov 28;2(8257):1227–1228. doi: 10.1016/s0140-6736(81)91460-4. [DOI] [PubMed] [Google Scholar]
  13. Mogensen K. E., Uzé G. Radioiodination of human alpha interferons by the chloramine T method. Methods Enzymol. 1986;119:267–276. doi: 10.1016/0076-6879(86)19039-2. [DOI] [PubMed] [Google Scholar]
  14. Panem S., Check I. J., Henriksen D., Vilcek J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J Immunol. 1982 Jul;129(1):1–3. [PubMed] [Google Scholar]
  15. Paul W. E., Seder R. A. Lymphocyte responses and cytokines. Cell. 1994 Jan 28;76(2):241–251. doi: 10.1016/0092-8674(94)90332-8. [DOI] [PubMed] [Google Scholar]
  16. Pozzetto B., Mogensen K. E., Tovey M. G., Gresser I. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis. 1984 Nov;150(5):707–713. doi: 10.1093/infdis/150.5.707. [DOI] [PubMed] [Google Scholar]
  17. Prümmer O., Frickhofen N., Digel W., Heimpel H., Porzsolt F. Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann Hematol. 1991 Feb-Mar;62(2-3):76–80. doi: 10.1007/BF01714905. [DOI] [PubMed] [Google Scholar]
  18. Prümmer O., Seyfarth C., Scherbaum W. A., Drees N., Porzsolt F. Interferon-alpha antibodies in autoimmune diseases. J Interferon Res. 1989 Sep;9 (Suppl 1):S67–S74. [PubMed] [Google Scholar]
  19. Ross C., Hansen M. B., Schyberg T., Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol. 1990 Oct;82(1):57–62. doi: 10.1111/j.1365-2249.1990.tb05403.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Steis R. G., Smith J. W., 2nd, Urba W. J., Clark J. W., Itri L. M., Evans L. M., Schoenberger C., Longo D. L. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med. 1988 Jun 2;318(22):1409–1413. doi: 10.1056/NEJM198806023182201. [DOI] [PubMed] [Google Scholar]
  21. Svenson M., Bagge Hansen M., Bendtzen K. Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera. Scand J Immunol. 1990 Dec;32(6):695–701. doi: 10.1111/j.1365-3083.1990.tb03212.x. [DOI] [PubMed] [Google Scholar]
  22. Svenson M., Hansen M. B., Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest. 1993 Nov;92(5):2533–2539. doi: 10.1172/JCI116862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Trown P. W., Kramer M. J., Dennin R. A., Jr, Connell E. V., Palleroni A. V., Quesada J., Gutterman J. U. Antibodies to human leucocyte interferons in cancer patients. Lancet. 1983 Jan 15;1(8316):81–84. doi: 10.1016/s0140-6736(83)91737-3. [DOI] [PubMed] [Google Scholar]
  24. Turano A., Balsari A., Viani E., Landolfo S., Zanoni L., Gargiulo F., Caruso A. Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4447–4451. doi: 10.1073/pnas.89.10.4447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. von Wussow P., Freund M., Block B., Diedrich H., Poliwoda H., Deicher H. Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet. 1987 Sep 12;2(8559):635–636. doi: 10.1016/s0140-6736(87)93034-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES